Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method-Reference-Cited by-同舟云学术

Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method

Published:2023-02-17 Issue:2 Volume:6 Page:76-86
ISSN:2516-4236
Container-title:Antibody Therapeutics
language:en
Short-container-title:

Author:

Dou Yang¹²^ORCID,Xu Ke³,Deng Yong-Qiang⁴,Jia Zijing⁵⁶,Lan Jun⁷⁸,Xu Xiaoyu⁹,Zhang Guorui¹⁰,Cao Tianshu⁵⁶,Liu Pan⁵⁶,Wang Xiangxi⁵⁶,Wang Xinquan⁷⁸,Xu Lingjie⁹,Du Pan⁹,Qin Cheng-Feng⁴,Liu Hong¹⁰,Li Yafeng¹¹,Wu Guizhen³,Wang Kang⁵⁶,Lu Bai¹²

Affiliation:

1. School of Pharmaceutical Sciences , IDG/McGovern Institute for Brain Research, , Beijing 100084 , China

2. Tsinghua University , IDG/McGovern Institute for Brain Research, , Beijing 100084 , China

3. NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention , Beijing 102206 , China

4. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS , Beijing 100071 , China

5. National Laboratory of Macromolecules , Institute of Biophysics, , Beijing 100101 , China

6. Chinese Academy of Sciences , Institute of Biophysics, , Beijing 100101 , China

7. Beijing Advanced Innovation Center for Structural Biology , School of Life Sciences, , Beijing 100084 , China

8. Tsinghua University , School of Life Sciences, , Beijing 100084 , China

9. Vazyme Biotech Co., Ltd. , Nanjing , China

10. Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University , Zhengzhou 450052 , China

11. Shanxi Provincial Key Laboratory of Kidney Disease, The Fifth Hospital of Shanxi Medical University , Taiyuan 030012 , China

Abstract

AbstractBackgroundRapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients.MethodsHere, we report a high-throughput single-B-cell cloning method for high-throughput isolation of nAbs targeting diverse epitopes on the SARS-CoV-2-RBD (receptor binding domain) from convalescent COVID-19 patients. This method is simple, fast and highly efficient in generating SARS-CoV-2-neutralizing antibodies from COVID-19 patients’ B cells.ResultsUsing this method, we have developed multiple nAbs against distinct SARS-CoV-2-RBD epitopes. CryoEM and crystallography revealed precisely how they bind RBD. In live virus assay, these nAbs are effective in blocking viral entry to the host cells.ConclusionThis simple and efficient method may be useful in developing human therapeutic antibodies for other diseases and next pandemic.

Funder

Vazyme Biotech and Tsinghua University

Publisher

Oxford University Press (OUP)

Subject

Immunology,Immunology and Allergy

Link

https://academic.oup.com/abt/advance-article-pdf/doi/10.1093/abt/tbad002/49501404/tbad002.pdf

Reference45 articles.

1. How bad is Omicron? What scientists know so far;Callaway;Nature,2021

2. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor;Hoffmann;Cell,2020

3. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein;Walls;Cell,2020

4. Structural and functional basis of SARS-CoV-2 entry by using human ACE2;Wang;Cell,2020

5. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation;Wrapp;Science,2020